NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global systemic mastocytosis treatment market size is estimated to grow by USD 157.1 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 6.2% during the forecast period. Growth of aging population is driving market growth, with a trend towards advancements in diagnostic technologies for systemic mastocytosis treatment.
However, high cost associated with systemic mastocytosis treatment poses a challenge.Key market players include A. Menarini Industrie Farmaceutiche Riunite Srl, AB Science SA, AdvaCare Pharma, BDR Pharmaceuticals Internationals Pvt.
Ltd, Blueprint Medicines Corp., Dr Reddys Laboratories Ltd., F.
Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
, Lupin Ltd., NOVA PHARMA LLC, Novartis AG, Ono Pharmaceutical Co. Ltd.
, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co.
Ltd., and Zydus Lifesciences Ltd..
AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth The systemic mastocytosis treatment market is experiencing notable progress, particularly in diagnostic technologies. Genetic testing plays a crucial role in diagnosing systemic mastocytosis, specifically for identifying KIT mutations like D816V.
This advancement enables per.
